Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
03/2005
03/08/2005US6864094 Method of preserving oxygen infusions
03/08/2005US6863914 Stable, aqueous dispersions and stable, water-dispersible dry powders of xanthophylls, and production and use of the same
03/08/2005US6863907 Persimmon leaf or its extract; treating skin disorders
03/08/2005US6863904 Compositions and methods for prophylactic and therapeutic supplementation of nutrition in subjects
03/08/2005US6863902 Mixture of methyl hydrogen 9,11 alpha-epoxy-17 alpha-hydroxy-3-oxopregn-4-ene-7-alpha, 21-dicarboxylate, gamma-lactone and carriers administered as aldosterone receptor antagonists, for prophylaxis of cardiovascular disorders
03/08/2005US6863901 Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration
03/08/2005US6863898 Method and composition for treating hairy hoof warts
03/08/2005US6863891 Oligopeptide lyophilisate, their preparation and use
03/08/2005CA2351848C Method for increasing pet activity
03/08/2005CA2349672C Method for preparing capsules consisting of a liquid active material core enclosed in a mineral coating
03/08/2005CA2162716C Inclusion complexes of taxol or taxotere or taxus extract formed with cyclodextrins, its preparation and use
03/03/2005WO2005019429A2 Compositions and methods for enhancing phagocytosis or phagocyte activity
03/03/2005WO2005019260A1 INTERFERON-β COMPOSITE
03/03/2005WO2005019233A1 Mitoquinone derivatives used as mitochondrially targeted antioxidants
03/03/2005WO2005019232A1 Mitoquinone derivatives used as mitochondrially targeted antioxidants
03/03/2005WO2005019212A1 Compounds, methods and formulations for the oral delivery of a glucagon like peptide (glp)-1 compound or an melanocortin 4 receptor (mc4) agonist peptide
03/03/2005WO2005019184A1 Compounds, methods and formulations for the oral delivery of a glucagon like peptide (glp)-1 compound or an melanocortin 4 receptor (mc4) agonist peptide
03/03/2005WO2005018697A2 Active agent delivery systems, including a single layer of a miscible polymer blend, medical devices, and methods
03/03/2005WO2005018679A1 A hybrid of free-base amlodipine with a layered silicate and a process for preparing the same
03/03/2005WO2005018678A1 Additives for tablet
03/03/2005WO2005018646A1 Ophthalmic composition
03/03/2005WO2005018607A1 Medicinal preparation having improved dissolution properties
03/03/2005WO2005018602A2 Method for the production of effervescent granules in a vacuum
03/03/2005WO2005018585A1 Pharmaceutical and cosmetic formulations for treating fingernails
03/03/2005WO2005018582A2 Compositions containing topical active agents and pentylene glycol
03/03/2005WO2005018572A2 Improved antibodies having altered effector function and methods for making the same
03/03/2005WO2005018538A2 Severe acute respiratory syndrome (sars) polypeptides, antibodies to sars polypeptides and the use thereof in diagnostic, vaccination and therapeutic applications
03/03/2005WO2005018323A1 Edible films for administration of medicaments to animals
03/03/2005WO2004112747A3 Specific delivery of drugs to the brain
03/03/2005WO2004108071A3 Targeting polypeptides to the central nervous system
03/03/2005WO2004091536A3 An albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
03/03/2005WO2004091530A3 Homogeneous, thermoreversible gel film containing kappa-2 carrageenan and soft capsules made therefrom
03/03/2005WO2004087100A3 Cladribine formulations for improved oral and transmucosal delivery
03/03/2005WO2004084859A3 Nasal calcitonin formulations containing chlorobutanol
03/03/2005WO2004073640A3 Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
03/03/2005WO2004063213A3 Peptides which target tumor and endothelial cells, compositions and uses thereof
03/03/2005WO2004001058A3 Transcription factor modulating compounds and methods of use thereof
03/03/2005US20050050191 Storage network and method for storage network device mapping
03/03/2005US20050049359 Amelioration of ischemic damage using synthetic oxygen carriers
03/03/2005US20050049314 Buffering; near neutral to slightly alkaline pH
03/03/2005US20050049291 Process for the preparation of pharmaceutical compositions for topical delivery of cyclooxygenase-2-enzyme inhibitors
03/03/2005US20050049233 Transdermal administering of testosterone
03/03/2005US20050049232 Preventing hair loss and/or stimulating growth; active ingredient combined with lipophilic and hydrophilic two phase system; creates semipermeable membrane in skin holding medication in appropriate area; reduced irritation and systemic effects
03/03/2005US20050049223 Basic drug compositions with enhanced bioavailability
03/03/2005US20050049216 Immunostimulatory nucleic acid molecules
03/03/2005US20050049215 contain unmethylated cytosine-guanine (CpG) dinucleotides; stimulating interferon-alpha to treat viral infections; oligonucleotide linked to a biodegradable delivery complex
03/03/2005US20050049213 Method for preventing or reversing asthma and compositions useful therefor
03/03/2005US20050049210 Methods for the controlled delivery of pharmacologically active compounds
03/03/2005US20050049209 Pharmaceutical compositions for delivering macrolides
03/03/2005US20050049182 Therapeutic formulation comprising cationic peptide, viscosity-increasing agent, and solvent, wherein the cationic peptide contains up to 35 amino acids; use in treating or preventing infectious disease associated with foreign bodies, primary or seconary infection sites
03/03/2005US20050048507 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
03/03/2005US20050048144 Herb extract-based cosmeceutical cream for controlling the blood sugar level of diabetes and methods for making it
03/03/2005US20050048123 Liquid sustained release ; in situ injecting of water insoluble gel in polyoxyethylene glycol solvent
03/03/2005US20050048121 Sustained release; acylation, dehydration a diacid in presence of nonaqueous solvent
03/03/2005US20050048111 Atopic dermatitis treatment method
03/03/2005US20050048108 Using cephalins as complexing agent for gene therapy, diagnosis
03/03/2005US20050048107 Administering as a transdermal patch comprising oxybutynin to provide a plasma area under the curve (AUC) ratio of oxybutynin to an oxybutynin metabolite of from about 0.5:1 to about 5:1 with a peak oxybutynin metabolite plasma concentration of less than about 8 ng/ml
03/03/2005US20050048106 Administering as a transdermal patch comprising oxybutynin to provide a plasma area under the curve (AUC) ratio of oxybutynin to an oxybutynin metabolite of from about 0.5:1 to about 5:1 with a peak oxybutynin metabolite plasma concentration of less than about 8 ng/ml
03/03/2005US20050048104 Transdermal drug delivery devices comprising a polyurethane drug reservoir
03/03/2005US20050048098 Semirigid eye implant; glycolic acid-lactic acid copolymer and release moderator for dexamethasome;
03/03/2005US20050048087 Mixture of fatty ester, lipophilic excipient and nonionic surfactant as solubilizer for drugs such as cyclosporin a and cyclosporin g; bioavailability
03/03/2005US20050048079 Induction response in cells; joining to adenosine triphosphate binding domain; therapy for Aids; anticancer agents
03/03/2005US20050048064 Chemical modification of single chain polypeptides by means of covalent attachment of strands of polyethylene glycol to single chain polypeptide binding molecules that have three dimensional folding and binding ability
03/03/2005US20050048060 Immunoconjugates
03/03/2005US20050048059 Binding to epitope which contains peptide and carbohydrate on tumor; anticancer agents
03/03/2005US20050048049 A humanized antibody that binds to soluble A beta; may be monoclonal, polyclonal, single chain or fused to a heterologous polypeptide
03/03/2005US20050048044 Controlling, adjustment diffusion or degradation of membrane using activating energy source such as light source or ultraviolet radiation
03/03/2005US20050048043 Methods for in vivo gene transfer into pancreatic and biliary epithelial cells
03/03/2005US20050048026 Remedies for ischemic diseases
03/03/2005US20050048024 Compounds for use as surfactants
03/03/2005US20050048002 Method for delivering drugs to the brain
03/03/2005US20050047999 Matrix metalloproteinase inhibitors
03/03/2005US20050047958 Methods for sterilizing preparations of digestive enzymes
03/03/2005DE10335796A1 Verschliessen von Bakterienghosts durch bioaffine Wechselwirkungen Closing of bacterial ghosts by bioaffinity interactions
03/03/2005DE10331879A1 Wirkstofftransportsystem Drug delivery system
03/03/2005DE102004028415A1 Dermales oder transdermales therapeutisches System enthaltend eine Abdeckfolie mit Barrierewirkung The dermal or transdermal therapeutic system comprising a cover sheet with barrier effect
03/03/2005CA2776692A1 Penetrating pharmaceutical foam
03/03/2005CA2536643A1 Interferon-.beta. complex
03/03/2005CA2536408A1 Improved antibodies having altered effector function and methods for making the same
03/03/2005CA2536359A1 Cytotoxicity mediation of cells evidencing surface expression of cd44
03/03/2005CA2536283A1 Pharmaceutical preparations having an improved solubility
03/03/2005CA2535346A1 Active agent delivery systems, including a single layer of a miscible polymer blend, medical devices, and methods
03/02/2005EP1510224A1 In vivo gene transfer methods for wound healing
03/02/2005EP1510223A1 Intravenous composition, process for producing the same and preparation thereof
03/02/2005EP1510220A1 Therapeutic inhibitor of vascular smooth muscle cells
03/02/2005EP1510215A1 Novel solid preparation containing block copolymer and anthracycline anticancer agent and process for producing the same
03/02/2005EP1510213A2 Penetration enhancing and irritation reducing systems comprising testosterone
03/02/2005EP1510205A1 Universal controlled-release composition comprising xanthan gum and sodium alginate
03/02/2005EP1509533A1 Polyol-modified silanes as precursors for silica
03/02/2005EP1509268A1 Drug delivery assembly
03/02/2005EP1509255A1 Methods and compositions for intravesical therapy of bladder cancer
03/02/2005EP1509249A2 Inclusion complexes of rosiglitazone
03/02/2005EP1509246A2 Thermosensitive polymer carriers having a modifiable physical structure for biochemical analysis, diagnosis, and therapy
03/02/2005EP1509243A1 Topical drug delivery using phosphatidylcholine
03/02/2005EP1509237A2 Methods of treating angiogenesis, tumor growth, and metastasis
03/02/2005EP1509235A1 Method for the protection of endothelial and epithelial cells during chemotherapy
03/02/2005EP1509233A1 Liquid formulation of decitabine and use of the same
03/02/2005EP1509231A1 Peritoneal dialysis solution with taurolidine
03/02/2005EP1509227A1 A buffered, liquid nicotine composition for pulmonary administration
03/02/2005EP1509210A1 Plaster containing fentanyl
1 ... 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 ... 1712